|
|
| | Daclatasvir impurity 15/N-[(1S)-1-[[(2S)-2-[5-[4’-[2-[(2S)-1-Acetyl-2-pyrrolidinyl]-1H-imidazol-5-yl][1,1’-biphenyl]-4-yl]-1H-imidazol-2-yl]-1-pyrrolidinyl]carbonyl]-2-methylpropyl]-methyl ester carbamic acid Basic information |
| Product Name: | Daclatasvir impurity 15/N-[(1S)-1-[[(2S)-2-[5-[4’-[2-[(2S)-1-Acetyl-2-pyrrolidinyl]-1H-imidazol-5-yl][1,1’-biphenyl]-4-yl]-1H-imidazol-2-yl]-1-pyrrolidinyl]carbonyl]-2-methylpropyl]-methyl ester carbamic acid | | Synonyms: | Daclatasvir impurity 15/N-[(1S)-1-[[(2S)-2-[5-[4’-[2-[(2S)-1-Acetyl-2-pyrrolidinyl]-1H-imidazol-5-yl][1,1’-biphenyl]-4-yl]-1H-imidazol-2-yl]-1-pyrrolidinyl]carbonyl]-2-methylpropyl]-methyl ester carbamic acid;Carbamic acid, N-[(1S)-1-[[(2S)-2-[5-[4'-[2-[(2S)-1-acetyl-2-pyrrolidinyl]-1H-imidazol-5-yl][1,1'-biphenyl]-4-yl]-1H-imidazol-2-yl]-1-pyrrolidinyl]carbonyl]-2-methylpropyl]-, methyl ester;N-[(1S)-1-[[(2S)-2-[5-[4'-[2-[(2S)-1-Acetyl-2-pyrrolidinyl]-1H-imidazol-5-yl][1,1'-biphenyl]-4-yl]-1H-imidazol-2-yl]-1-pyrrolidinyl]carbonyl]-2-methylpropyl]-, methyl ester carbamic acid;Methyl ((S)-1-((S)-2-(5-(4''-(2-((S)-1-acetylpyrrolidin-2-yl)-1H-imidazol-5-yl)-[1,1''-biphenyl]-4-yl)-1H-imidazol-2-yl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-yl)carbamate;Daclatasvir Impurity 16/Methyl ((S)-1-((S)-2-(5-(4'-(2-((S)-1-acetylpyrrolidin-2-yl)-1H-imidazol-5-yl)-[1,1'-biphenyl]-4-yl)-1H-imidazol-2-yl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-yl)carbamate;Mono-N-desvalinyl,-N-acetyl Daclatasvir;Daclatasvir Acetyl impurity: Methyl [(2S)-1-(2S)-2-[5-(4'-2-[(2S)-1-acetylpyrrolidin-2-yl]-1H-imidazol-5-ylbiphenyl -4-yl)-1H-imidazol-2-yl]pyrrolidin-1-yl-3-methyl-1-oxobutan-2-yl]carbamate | | CAS: | 2226541-13-3 | | MF: | C35H41N7O4 | | MW: | 623.74 | | EINECS: | | | Product Categories: | | | Mol File: | 2226541-13-3.mol | ![Daclatasvir impurity 15/N-[(1S)-1-[[(2S)-2-[5-[4’-[2-[(2S)-1-Acetyl-2-pyrrolidinyl]-1H-imidazol-5-yl][1,1’-biphenyl]-4-yl]-1H-imidazol-2-yl]-1-pyrrolidinyl]carbonyl]-2-methylpropyl]-methyl ester carbamic acid Structure](CAS/20200611/GIF/2226541-13-3.gif) |
| | Daclatasvir impurity 15/N-[(1S)-1-[[(2S)-2-[5-[4’-[2-[(2S)-1-Acetyl-2-pyrrolidinyl]-1H-imidazol-5-yl][1,1’-biphenyl]-4-yl]-1H-imidazol-2-yl]-1-pyrrolidinyl]carbonyl]-2-methylpropyl]-methyl ester carbamic acid Chemical Properties |
| Boiling point | 1013.9±65.0 °C(Predicted) | | density | 1.258±0.06 g/cm3(Predicted) | | pka | 11.22±0.46(Predicted) |
| | Daclatasvir impurity 15/N-[(1S)-1-[[(2S)-2-[5-[4’-[2-[(2S)-1-Acetyl-2-pyrrolidinyl]-1H-imidazol-5-yl][1,1’-biphenyl]-4-yl]-1H-imidazol-2-yl]-1-pyrrolidinyl]carbonyl]-2-methylpropyl]-methyl ester carbamic acid Usage And Synthesis |
| Uses | N-[(1S)-1-[[(2S)-2-[5-[4''-[2-[(2S)-1-Acetyl-2-pyrrolidinyl]-1H-imidazol-5-yl][1,1''-biphenyl]-4-yl]-1H-imidazol-2-yl]-1-pyrrolidinyl]carbonyl]-2-methylpropyl]-, methyl ester carbamic acid is an impurity of Daclatasvir (D101500), which inhibits the HCV protein NS5A, and thus can be used as a drug candidate for the treatment of hepatitis C (HCV). |
| | Daclatasvir impurity 15/N-[(1S)-1-[[(2S)-2-[5-[4’-[2-[(2S)-1-Acetyl-2-pyrrolidinyl]-1H-imidazol-5-yl][1,1’-biphenyl]-4-yl]-1H-imidazol-2-yl]-1-pyrrolidinyl]carbonyl]-2-methylpropyl]-methyl ester carbamic acid Preparation Products And Raw materials |
|